Clinical Trial Update: Ketohexokinase Inhibition in NAFLD [Phase 2]

View source ↗

Summary

Phase 2 clinical trial examining ketohexokinase inhibition for nonalcoholic fatty liver disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease

Snippet

Sponsor: Maastricht University Medical Center | Conditions: NAFLD | Phase 2 | Status: COMPLETED